#ICYMI: We spoke with @ICR_London & @royalmarsdenNHS ECMC Lead, Johann De Bono who found targeting #Myeloid cells may reverse drug resistance in #ProstateCancer. Read more about the trial, what it showed and what they will do next 👉 https://t.co/htaMd6OUWw
💬🚨"This research proves for the first time that targeting #Myeloid cells can shrink tumours. This suggests we have an entirely new way to treat #ProstateCancer on the horizon.''
- Prof Johann De Bono, Professor in Experimental #CancerMedicine
https://t.co/aFlNlrrVi3
👩🔬 It's #AdaLovelaceDay - a time to celebrate the incredible work of the ICR's #WomenInSTEM!
Denisa Bogdan, Bioinformatician in the #Cancer Biomarkers Team, shares her thoughts on #AdaLovelace and gives advice to young women interested in this field👇
#WomenInScience
Articles in Press: A Transgender Patient with Prostate Cancer: Lessons Learnt
https://t.co/ywCABCXE51
"There is a need for studies to evaluate PC risk in transgender women. Studies should evaluate whether oestrogen supplementation fuels prostate carcinogenesis"